Aselizumab
From Wikipedia, the free encyclopedia
|
Aselizumab
|
|
|
|
|
| Source | Human |
| Target | CD62 |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Aselizumab is an immunosuppressive drug. It binds to CD62L.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Abatacept, Abetimus, Adalimumab, Afelimomab, Anakinra, Alefacept, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit), Aselizumab, Atlizumab, Atorolimumab, Azathioprine, Basiliximab, Belatacept, Belimumab, Bertilimumab, Cedelizumab, Ciclosporin, Citilimumab, Clenoliximab, Daclizumab, Difirolimus, Dofosirolimus, Dorlimomab aritox, Eculizumab, Efalizumab, Elsilimomab, Enlimomab, Enlimomab pegol, Erlizumab, Etanercept, Everolimus, Faralimomab, Fontolizumab, Galiximab, Gavilimomab, Gifosirolimus, Golimumab, Gomiliximab, Gusperimus, Infliximab, Inolimomab, Ipilimumab, Keliximab, Leflunomide, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Methotrexate, Morolimumab, Muromonab-CD3, Mycophenolic acid, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Pascolizumab, Pexelizumab, Pimecrolimus, Reslizumab, Rovelizumab, Ruplizumab, Safosirolimus, Siplizumab, Sirolimus, Tacrolimus, Talizumab, Telimomab aritox, Teneliximab, Thalidomide, Ticilimumab, Tilolizumab, Tocilizumab, Toralizumab, Torolimus, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
Alemtuzumab, Apolizumab, Aselizumab, Atlizumab, Bapineuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Cedelizumab, Certolizumab pegol, Cidfusituzumab, Cidtuzumab, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Felvizumab, Fontolizumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Mepolizumab, Motavizumab, Motovizumab, Natalizumab, Nimotuzumab, Nolovizumab, Numavizumab, Ocrelizumab, Omalizumab, Palivizumab, Pascolizumab, Pecfusituzumab, Pectuzumab, Pertuzumab, Pexelizumab, Ralivizumab, Ranibizumab, Reslivizumab, Reslizumab, Resyvizumab, Rovelizumab, Ruplizumab, Sibrotuzumab, Siplizumab, Sontuzumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tefibazumab, Tocilizumab, Toralizumab, Trastuzumab, Tucotuzumab celmoleukin, Tucusituzumab, Umavizumab, Urtoxazumab, Visilizumab
